CTS.AU Ceretas Limited
- Market cap
- AUD 65.7M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is CTS.AU undervalued?
Graham numberThe Graham number of Ceretas Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ceretas Limited fundamental analysis
No fundamental analysis for Ceretas Limited yet.
Ceretas Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ceretas Limited
Ceretas Limited, a medical technology company that develops portable and non-invasive therapeutic ultrasound platform for the treatment of Alzheimer's disease and other neurodegenerative conditions in Australia. The company's technology operates through two primary mechanisms, including neuromodulation, which uses low-intensity focused ultrasound to stimulate neural circuits; and BBBO, which temporarily and reversibly opens the blood-brain barrier using ultrasound combined w…
Full company profileFinancial statements of Ceretas Limited are not available yet.
Ceretas Limited dividends
Ceretas Limited has not paid dividends in the last 1 fiscal years.
Who owns Ceretas Limited
- Insiders 73.81%
- Institutions 0.00%
- Public & others 26.19%
- Shares outstanding 71.4M
- Free float 37.1M
Ceretas Limited company profile
- Company name
- Ceretas Limited
- Ticker
- CTS.AU
- ISIN
- AU0000475766
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Fiscal year end
- June
- Address
- 348 Edward Street, Brisbane, QLD, Australia, 4000
- Phone
- 61 7 3543 4424
- Website
- ceretas.com.au
About Ceretas Limited
Ceretas Limited, a medical technology company that develops portable and non-invasive therapeutic ultrasound platform for the treatment of Alzheimer's disease and other neurodegenerative conditions in Australia. The company's technology operates through two primary mechanisms, including neuromodulation, which uses low-intensity focused ultrasound to stimulate neural circuits; and BBBO, which temporarily and reversibly opens the blood-brain barrier using ultrasound combined with circulating microbubbles that facilitates brain's natural clearance of amyloid-beta and tau and helps delivery of co-administered drugs to targeted brain regions. Ceretas Limited was incorporated in 2024 and is based in Brisbane, Australia.
Ceretas Limited management
5- Dr. Rachel de las HerasCo-Founder, CEO, MD & Executive Director
- Mr. Sam WetzlerCo-Founder & Non-Executive Director
- Mr. Vesa PeltonenChief Technology Officer
- Dr. Anthony James KeatingExecutive Director
- Ms. Nicki Farley B.A., L.L.B.Company Secretary · born 1976